News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rumor: Sarepta Therapeutics (SRPT) Chairman Moves To Keep CEO Out Of FDA Meetings


7/30/2014 6:38:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The board of Sarepta Therapeutics has taken actions to limit CEO Chris Garabedian’s role at the company and to keep him from attending meetings with the FDA, The Wall Street Journal cites anonymous sources as saying.

The WSJ said that two people familiar with the matter told the paper that Sarepta (Nasdaq: SRPT) Chairman William Goolsbee told the executive team in July, at a meeting that Garabedian attended, that he “would no longer attend ... meetings with the FDA.” The sources also reportedly said that Garabedian would no longer have a “final say in decisions about clinical trial design and patient safety.”

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES